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Introduction {#sec1}
============

CDC7 is a conserved Ser/Thr kinase, which, in addition to its essential role in activation of DNA replication origins (reviewed in [@bib66]), is implicated in intra S-phase checkpoint ([@bib14], [@bib16], [@bib77], [@bib81], [@bib84]), DNA repair ([@bib63]), mitotic exit ([@bib50], [@bib51]), meiosis ([@bib6], [@bib35], [@bib43], [@bib46], [@bib54], [@bib58], [@bib67], [@bib80]), and chromosome cohesion ([@bib56], [@bib75]). Catalytically inert in isolation, CDC7 becomes functional in complex with Dumbbell forming factor 4 (DBF4), the levels of which fluctuate throughout the cell cycle ([@bib19], [@bib31], [@bib60]). The activity of CDC7 peaks at the G~1~/S-phase transition and is maintained throughout S phase, during which the kinase fulfills its primary role of phosphorylating components of the replisome to facilitate loading of firing factors and subsequent DNA unwinding ([@bib31], [@bib60]). Well-characterized targets of phosphorylation by CDC7 are subunits of the heterohexameric replicative DNA helicase MCM2--MCM7. CDC7-mediated phosphorylation of MCM2 and MCM4 appears to be particularly important in humans and yeast, respectively ([@bib45], [@bib53], [@bib64], [@bib71]). In addition, CDC7 was implicated in phosphorylation of proteins involved in meiosis, DNA repair, and gene expression ([@bib5], [@bib26], [@bib80]). While substrate recognition by CDC7 likely involves interactions with substrate regions distal to the phosphate acceptor residue ([@bib70]), characterized phosphorylation sites share an acidic or a pre-phosphorylated residue at P+1 position ([@bib11], [@bib26], [@bib53], [@bib63]).

CDC7 and DBF4 tend to be overexpressed in primary cancers and tumor cell lines, and their levels negatively correlate with patient prognosis ([@bib4], [@bib9], [@bib12], [@bib22], [@bib23], [@bib30], [@bib40], [@bib49], [@bib73], [@bib86]). Selective inhibition of CDC7 suppresses proliferation of transformed cells through induction of S-phase delay and replication stress ([@bib10], [@bib27], [@bib28], [@bib29], [@bib52]). Furthermore, CDC7 antagonists showed promise in combination with other cell-cycle inhibitors and anti-cancer therapeutics ([@bib7], [@bib20], [@bib57]). Selective inhibitors of CDC7 are being developed and trialed as anti-cancer therapeutics, with a number of candidate drugs undergoing clinical trials ([@bib10], [@bib21], [@bib24], [@bib29], [@bib39], [@bib41], [@bib68], [@bib74], [@bib79]). The efforts to develop small-molecule inhibitors will greatly benefit from high-resolution structural information.

CDC7 possesses the canonical bilobal kinase fold, which is interrupted by unique kinase inserts (KIs). Human CDC7 harbors two such inserts: KI-2 (residues 202--373), extending the kinase activation loop, and KI-3 (residues 433--539) separating the αG and αH helices of the C lobe ([Figure 1](#fig1){ref-type="fig"}A). DBF4 is predicted to be largely unstructured, harboring only three short conserved motifs N, M, and C ([Figure 1](#fig1){ref-type="fig"}A) ([@bib44]). DBF4 motif N features an extended BRCT fold and is implicated in the interactions with the checkpoint kinase RAD53 and the origin recognition complex ([@bib47]). Motifs M and C, collectively comprising residues 215--330 of human DBF4, are necessary and sufficient to stimulate CDC7 kinase ([@bib38], [@bib59]).Figure 1Design and Activity of CDC7 Deletion Constructs(A) Schematic of human CDC7 and DBF4. Locations of kinase inserts (KI-2 and KI-3) in CDC7 and conserved motifs in DBF4 (N, M, and C) are indicated. Deletions in CDC7 (Δ1--36, Δ228--345, and Δ467--533) and the span of the DBF4 fragment used for crystallography in this work are shown above the schematics.(B) *In vitro* kinase activities of WT full-length or deleted CDC7 constructs produced in complex with DBF4^MC^ with or without treatment with λ phage protein phosphatase (λPPase). Activities were normalized to WT kinase pre-treated with phosphatase. The bar plots show mean values with standard deviations from triplicate measurements.(C) Effects of deletions in KI-2 and KI-3 on *in vitro* kinase activities of CDC7(Δ1--36)-DBF4^MC^. The KI-2 deletion used for crystallography previously ([@bib25]) is Δ228--359; the rightmost bar reports relative activity of the construct used for crystallography in the current work. All constructs were pre-treated with λPPase, and activities were normalized to the construct with full-length inserts.Error bars represent standard deviations based on measurements done in triplicate.

A crystal structure of a heterodimeric human CDC7-DBF4 construct possessing partial kinase activity shed light on the catalytic core of the S-phase kinase ([@bib25]). The structure revealed an extensive bipartite kinase-activator interface, with DBF4 motifs C and M engaging CDC7 N and C lobes, respectively. In particular, the interactions involving DBF4 motif C are critical for orienting the canonical αC helix of CDC7. Crystallization required substantial deletions in KI-2 and KI-3 due to the inherent flexibility of these regions, and the deletion within KI-2 led to a considerable reduction of the kinase activity ([@bib25]). To identify the components of KI-2 important for the kinase activity, we determined crystal structures of a heterodimeric CDC7-DBF4 construct with improved activity in the absence and presence of a bound MCM2-derived substrate peptide. The structures reveal a Zn-binding domain in KI-2 of CDC7 that pins back the activation loop and opens up the active site for substrate binding. We also show that invariant CDC7 residues Arg373 and Arg380 are critical for the interactions with an acidic P+1 residue of the substrate.

Results {#sec2}
=======

Identification and Crystallization of a CDC7-DBF4 Construct with Improved Activity {#sec2.1}
----------------------------------------------------------------------------------

The presence of extended disordered regions in CDC7 and DBF4 presents a challenge to crystallization of the heterodimer. The previously characterized construct comprised CDC7 mutant lacking the first 36 amino acids (Δ1--36), which are predicted to be disordered, in addition to the deletions of residues 228--359 in KI-2 and 484--529 in KI-3, in complex with a fragment of DBF4 spanning motifs M and C (referred to as DBF4^MC^, residues 210--350) ([@bib25]). The heterodimer retained partial functionality in an *in vitro* kinase assay, and the loss of activity was attributed to the deletion in KI-2 ([@bib26]). To identify constructs with improved kinase function, we prepared a set of CDC7(Δ1--36)-DBF4^MC^ constructs harboring nested deletions within KI-2. Active CDC7-DBF4 constructs can undergo extensive autophosphorylation during expression in bacteria ([@bib26]), which strongly inhibits activity of the enzyme ([Figure 1](#fig1){ref-type="fig"}B). Therefore, CDC7-DBF4 heterodimers were isolated using a modified protocol, which incorporated a phosphatase treatment to reverse autophosphorylation. The proteins were tested in an *in vitro* kinase assay using a biotinylated peptide spanning residues 35--47 of human MCM2 that contains the CDC7 target residue Ser40 and is primed by phosphorylation on Ser41 ([@bib53]). Deletion of CDC7 KI-2 residues 228--359 resulted in over 50-fold reduction in activity ([Figure 1](#fig1){ref-type="fig"}C), confirming the importance of KI-2. The defect associated with the deletion was considerably more pronounced than reported previously with non-dephosphorylated proteins. This is not surprising, because the most catalytically robust constructs, such as the heterodimers containing complete KI-2, are subject to more efficient inhibitory auto-phosphorylation. Strikingly, adding back as few as 10 amino acid residues at the end of the KI-2 was sufficient to restore the *in vitro* kinase activity ([Figure 1](#fig1){ref-type="fig"}C).

To facilitate crystallization of the catalytically competent constructs, we replaced 22 KI-3 residues retained in the previously characterized construct, but not visible in the structure, with a pentapeptide linker Gly-Ala-Gly-Ala-Gly (the deletion designated Δ467--533). The modification did not affect the kinase activity *in vitro* ([Figure 1](#fig1){ref-type="fig"}C). Crystals were obtained with CDC7(Δ1--36/Δ228--345/Δ467--533)-DBF4^MC^ heterodimer, which retained full activity compared with the matched control harboring complete KI-2 and KI-3 ([Figure 1](#fig1){ref-type="fig"}C). X-ray diffraction data were collected using crystals grown in the presence of the ATP-competitive CDC7 inhibitor XL413 ([@bib39]). To visualize the CDC7 active site in a functional state, we used the drug-bound form to nucleate crystals in the presence of the ground-state ATP mimic ADP-BeF~3~^−^ ([@bib34]).

A Zinc-Binding Domain in CDC7 KI-2 Is Critical for Kinase Activity {#sec2.2}
------------------------------------------------------------------

Crystal structures of the XL413-bound and nucleotide-bound complexes were refined to 1.4 and 1.8 Å resolution, respectively ([Figures 2](#fig2){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}; [Table 1](#tbl1){ref-type="table"}). The structures are highly similar to that of the previously characterized construct ([@bib25]), with the root-mean-square deviations (RMSDs) of common αC atom positions between the two constructs of ∼0.6 Å ([Figure S1](#mmc1){ref-type="supplementary-material"}). As reported previously, DBF4 motif C (residues 292--347) comprises a compact Zn-binding domain followed by a short α helix and an extended peptide that together wrap around the CDC7 N lobe. These interactions were previously shown to modulate the kinase activity via CDC7 αC ([@bib25]). DBF4 motif M (residues 210--254) forms a three-stranded β sheet with KI-3 and uses extended coiled regions to wrap around the C lobe of CDC7. As in the previous crystal structures, the linker region connecting DBF4 motifs C and M, comprising 37 residues, is disordered ([Figure 2](#fig2){ref-type="fig"}A).Figure 2Crystal Structure of CDC7(Δ1--36/Δ228--345/Δ467--533)-DBF4^MC^ Heterodimer in Complex with ADP-BeF~3~^−^(A) Overview of the structure. Protein chains are shown as cartoons and colored as in [Figure 1](#fig1){ref-type="fig"}A, with DBF4 in blue, canonical kinase CDC7 regions in green, and unique elements in yellow (N-terminal region), orange (KI-2), or red (KI-3). Zn and Mg atoms are shown as gray spheres, and nucleotide (ADP-BeF~3~) as sticks, with carbon atoms in pink and the remaining atoms according to standard conventions: nitrogen, oxygen, phosphorus, beryllium, and fluoride atoms in blue, red, orange, light green, and gray, respectively. Dotted lines show connectivity, where peptide linkages are disordered in the crystal structure. See [Figure S1](#mmc1){ref-type="supplementary-material"} for comparison with the structure of the previously reported construct ([@bib25]).(B) Left: stereo view of the KI-2 ZF domain and its interactions with DBF4. Selected residues are shown as sticks and indicated. Anomalous difference map calculated from diffraction data acquired using X-rays at the absorption K-edge of Zn (*λ* = 1.2837 Å) is shown as green mesh, contoured at 5σ; the peak height around the Zn atom is \>30σ. Right: relative kinase activities of CDC7(Δ1--36)-DBF4^MC^ constructs without (leftmost bar) and with Ala substitutions of the Zn-coordinating Cys residues.(C) Left: details of the active site. Final 2F~o~-F~c~ electron density map for the active-site region is shown in [Figure S2](#mmc1){ref-type="supplementary-material"}A. Right: superposition of the active sites of CDC7 and CDK2 (PDB: [3QHW](pdb:3QHW){#intref0120}) active sites bound to ATP analogs. Active-site Mg atoms are shown as gray spheres. Nucleotide analogs and selected amino acid residues are shown as sticks and labeled, colored as in (A) (CDC7) or with carbon atoms in gray (CDK2).Table 1X-Ray Data Collection and Refinement StatisticsLigandXL-413ADP-BeF~3~^−^ATPγS-S40-MCM2(33--47)PDB accession code[6YA6](pdb:6YA6){#intref0125}[6YA8](pdb:6YA8){#intref0130}[6YA7](pdb:6YA7){#intref0135}**Data Collection**[a](#tblfn1){ref-type="table-fn"}Wavelength (Å)1.03320.979570.97625Space groupP4~1~2~1~2P4~1~2~1~2P4~1~2~1~2Unit cell parameters *a*, *b*, *c* (Å)61.64, 61.64, 233.9161.15, 61.15, 235.4462.28, 62.28, 234.79 α, β, γ (^o^)90, 90, 9090, 90, 9090, 90, 90No. of crystals used111Resolution (Å)59.61--1.44 (1.491--1.44)58.86--1.79 (1.84--1.79)60.2--1.67 (1.71--1.67)No. of reflections Measured750,955493,033665,579 Unique82,61343,03754,941Completeness (%)99.6 (95.7)99.1 (90.2)99.96 (99.8)Multiplicity9.1 (6.4)11.5 (7.2)12.1 (8.5)\<*I*/σ(*I*)\>26.4 (2.7)23.6 (2.8)19.4 (3.3)*R*~merge~0.049 (0.584)0.067 (0.614)0.098 (0.724)CC~1/2~1.000 (0.77)0.999 (0.817)0.999 (0.81)**Refinement Statistics**Resolution range (Å)42.85--1.4448.24--1.7958.7--1.67No. of reflections Total82,48442,92954,918 Free4,1392,2082,739*R*~work~/*R*~free~0.1666/0.19330.1619/0.19370.1562/0.1852No. of atoms: Total4,0723,9174,135 Protein3,5693,5803,733 Ligands393536 Solvent464302366RMSDs from ideal Bond lengths (Å)0.0060.0070.010 Bond angles (^o^)0.870.881.15Average *B* factor (Å^2^)20.9526.5725.08Clashscore[b](#tblfn2){ref-type="table-fn"}1.662.493.99Favored rotamers[b](#tblfn2){ref-type="table-fn"}98.2297.2297.08Ramachandran plot (%)[b](#tblfn2){ref-type="table-fn"} Favored97.7098.1497.79 Disallowed0.2300[^3][^4]

The novel feature revealed by the crystal structures is found in the region spanning the end of KI-2 and the beginning of the CDC7 activation segment. Here, residues Cys351, Cys353, Cys360, and Cys363, all which are invariant among metazoan CDC7 orthologs, coordinate a single metal ion, nucleating zinc-finger (ZF) domain. We confirmed the presence of a Zn atom in the structure by anomalous diffraction ([Figure 2](#fig2){ref-type="fig"}B). The ZF domain nestles on motif M of DBF4, sandwiching it against the C lobe of CDC7 ([Figures 2](#fig2){ref-type="fig"}A and 2B). Crucially, this interaction pins back the beginning of the CDC7 activation loop, inducing it to adopt a stable conformation. Disruption of the ZF domain by a more extensive deletion that removed two of the four Zn^2+^ coordinating Cys residues explains why the activation loop was only partially ordered in the previously reported structure. In agreement with the importance of the ZF domain, substitutions of any of the four metal coordinating residues in the context of the complete KI-2 substantially reduced the kinase activity *in vitro* ([Figure 2](#fig2){ref-type="fig"}B).

Structural Basis for the Selectivity of CDC7 for Substrates with Acidic Residues at P+1 Position {#sec2.3}
------------------------------------------------------------------------------------------------

The organization of the CDC7 active site in complex with ADP-BeF~3~^−^ is strikingly similar to that observed in the substrate transition complex of CDK2 ([@bib2]). A pair of octahedrally coordinated Mg^2+^ ions is observed in contact with the BeF~3~^−^ moiety that mimics the γ-phosphate of the nucleotide substrate ([Figures 2](#fig2){ref-type="fig"}C and [S2](#mmc1){ref-type="supplementary-material"}A). Given that both the catalytic center and the activation loop, which underlies the substrate-binding platform, are well ordered in the structure, we carried out extensive screening to obtain crystals of the kinase bound to a target peptide. Co-crystallization was only successful using the bisubstrate approach ([@bib61]) with MCM2(33--47) peptide covalently conjugated to ATPγS via bromoacetyl-aminoalanine in place of Ser40 and pre-phosphorylated on Ser41. X-ray diffraction data were collected to 1.7-Å resolution ([Table 1](#tbl1){ref-type="table"}), and the structure was solved by molecular replacement. The nucleotide bound in the active site and nine residues of the substrate peptide, spanning MCM2 residues 38--46, were built in the resulting electron density map ([Figures 3](#fig3){ref-type="fig"}A and [S2](#mmc1){ref-type="supplementary-material"}B). No density could be attributed to the γ-phosphate moiety, presumably due to hydrolysis of the bisubstrate ligand during crystallization. Therefore, the present ligands were interpreted as ADP and the thioacetyl adduct of the MCM2 peptide ([Figures 3](#fig3){ref-type="fig"}A and [S2](#mmc1){ref-type="supplementary-material"}B).Figure 3Structural Basis for Substrate Binding by CDC7(A) Top: details of the interactions between ATPγS-S40-MCM2(33--47) bisubstrate adduct and CDC7. Note that the γ-phosphate moiety of the input bisubstrate has been hydrolyzed; see [Figure S2](#mmc1){ref-type="supplementary-material"}B for the final 2F~o~-F~c~ electron density map for that region of the structure. The substrate peptide is shown as sticks with carbon atoms in gray. Dotted lines indicate hydrogen-bond interactions. Bottom: same region of the structure, with CDC7 and DBF4 in surface representation.(B) Relative kinase activities of CDC7(Δ1--36)-DBF4^MC^ constructs without (leftmost bar) or with Ala substitutions of Arg373 and/or Arg380.(C) Relative activities of CDC7(Δ1--36)-DBF4^MC^ on MCM2(35--47) peptides with (all except second bar from the left) or without priming phosphorylation on Ser41 (second bar). Amino acid substitutions of Arg44 in substrate peptides are indicated below the plot.

The CDC7 target site consensus is limited to an acidic or pre-phosphorylated residue at substrate P+1 position ([@bib8], [@bib11]). In the crystal structure, the phosphate group on Ser41 of the target peptide, mimicking priming by CDK2, forms well-defined interactions with side chains of Arg373 and Arg380 ([Figure 3](#fig3){ref-type="fig"}A), invariant residues from the CDC7 activation loop and the C lobe, respectively. Accordingly, substitution of either or both of these residues to Ala compromised the kinase activity ([Figure 3](#fig3){ref-type="fig"}B). In addition to the interactions involving MCM2 phospho-Ser41, the side chain of Arg44, located in P+4 substrate position, is buried in a pocket lined by CDC7 and DBF4 residues. Within the pocket, MCM2 Arg44 makes a salt bridge with DBF4 Glu297 and hydrogen bonds with Ser96 and Gly198 of CDC7, stacking against CDC7 Phe96 ([Figure 3](#fig3){ref-type="fig"}A). However, the CDC7 target site consensus does not show conservation at P+4 position ([@bib8], [@bib11]), suggesting that the pocket may not be very selective. Concordantly, substitutions of Arg44 in the context of the substrate peptide resulted in relatively minor defects of the *in vitro* kinase activity, in sharp contrast to the near complete loss of phosphorylation upon removal of the priming phosphate on Ser41 ([Figure 3](#fig3){ref-type="fig"}C). These results further confirm the importance of the P+1 position as the major determinant for substrate specificity around the CDC7 active site.

Discussion {#sec3}
==========

DBF4 motifs M and C are collectively required to support CDC7 activity ([@bib38], [@bib59]), and we reported previously that binding of DBF4 motif C to the N lobe of CDC7 stabilizes the functional "in" conformation of αC ([@bib25]), which is a recurrent mechanism of protein kinase regulation ([@bib3], [@bib32], [@bib69], [@bib85]). The crystal structures described here reveal the unique role of DBF4 motif M: through the interaction with motif M, the KI-2 ZF domain pins the beginning of the CDC7 activation loop to the kinase C lobe, allowing it to adopt a stable conformation ([Figures 2](#fig2){ref-type="fig"}A, 2B, and [S1](#mmc1){ref-type="supplementary-material"}). Accordingly, substitutions of the Zn-coordinating Cys residues in the ZF domain affected the kinase activity *in vitro* ([Figure 2](#fig2){ref-type="fig"}B). A disruption of this domain was likely responsible for the reduced activity of the previously characterized construct ([@bib25]). The interactions involving the KI-2 ZF domain appear to functionally substitute those formed by phosphorylated residues in the kinases that are activated by phosphorylation of their activation segments. We conclude that CDC7 activity is controlled by DBF4 at two levels: (1) via ordering of the activation loop dependent on the ZF domain-DBF4 motif M interactions; and (2) via the control of αC insertion through by DBF4 motif C ([@bib25]). Of note, the flexible linkage of DBF4 motifs M and C (indeed, the 34-residue region separating them is disordered in our crystal structures) may allow additional finesse in the control of CDC7 activity. Sandwiched between CDC7 C lobe and KI-2 ZF domain, DBF4 motif M appears stably tethered to CDC7, possibly allowing motif C to engage and disengage from the N lobe without dissociation of the holoenzyme. Intriguingly, the Cys tetrad involved in Zn coordination is invariant across metazoan CDC7 orthologs but not in budding yeast. It is conceivable that a different mechanism is used for pinning back CDC7 activation loop by yeast DBF4. An interesting observation of this study was the apparent lack of requirement for significant portions of KI2 and KI3 for CDC7 kinase activity *in vitro*. The inserts, universally present in CDC7 orthologs, may participate in engaging binding partners and/or regulating various cellular functions of the kinase. Indeed, roles for KI-2 and KI-3 in nuclear import and export of CDC7 have been proposed ([@bib36], [@bib37]).

The ordering of the activation loop allowed co-crystallization of the kinase in complex with a target peptide. In our hands, a bisubstrate construct containing an MCM2-derived peptide covalently linked to ATPγS was invaluable in obtaining the crystals. Similar approaches facilitated co-crystallization of other protein kinases with their substrates and are being explored in kinase inhibitor development ([@bib15], [@bib42], [@bib61], [@bib62], [@bib65]). Although in the crystal structure the chimeric molecule was found in a hydrolyzed state, screening using unlinked peptide derivatives have not produced co-crystals. The substrate-bound structure revealed that CDC7 Arg373 and Arg380 make favorable interactions with substrate phosphorylated Ser41. These residues are invariant across CDC7 orthologs, suggesting a conserved mechanism for the recognition of the P+1 substrate residue, which is essential for the CDC7 kinase activity ([Figure 3](#fig3){ref-type="fig"}B). Additionally, the co-crystal structure revealed interactions involving MCM2 Arg44, a residue in the P+4 substrate position ([Figure 3](#fig3){ref-type="fig"}A). This observation is intriguing given that CDK2, which was implicated in priming at least some CDC7 target sites ([@bib53]), has a notable preference for Lys or Arg at its substrate P+3 position ([@bib72]). Thus, it is tempting to speculate that CDC7 evolved to work in tandem during activation of replication origins by the cyclin-dependent kinase(s). However, while the pocket is suited for accepting an Arg side chain, CDC7 does not appear to discriminate against target peptides with alternative residues in P+4 position ([Figure 3](#fig3){ref-type="fig"}C). Indeed, the interactions between the kinase and the P+1 residue had greater effects on the kinase activity ([Figures 3](#fig3){ref-type="fig"}B and 3C), further highlighting the importance of P+1 position within the limited target consensus sequence of CDC7. Our results reveal that both kinase inserts present in human CDC7, KI-2 and KI-3, mediate the interaction with DBF4 motif M ([Figure 2](#fig2){ref-type="fig"}A). However, extensive portions of both inserts are either missing or disordered in the crystallized constructs, and further work will be required to ascertain their roles. The current structures will be informative for the design of competitive active-site antagonists of CDC7 kinase. Furthermore, the multivalent CDC7-DBF4 interface described here may be utilized for the development of highly targeted non-competitive inhibitors.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Bacterial and Virus Strains**BL21(DE3)NovagenCat\# 69450Rosetta 2(DE3)NovagenCat\# 71400**Chemicals, Peptides, and Recombinant Proteins**λ phage protein phosphatase (λPPase), His~6~-taggedThis workN/AHRV14 3C protease, His~6~SUMO-taggedThis workN/ACDC7-DBF4 heterodimers (WT and mutants)This work and [@bib25]N/AATPγS-S40-MCM2(33-47) bisubstrate peptideThis workN/Abiotinylated MCM2(35-47) peptides (WT and mutants)This workN/AATPγSMerckCat\# 119120Rink Amide resinMerckCat\# 855120Fmoc-Dpr(Mtt)-OHMerckCat\# 852089**Critical Commercial Assays**SAM2 biotin-capture membrane assayPromegaCat\# V2861**Deposited Data**Initial model used for molecular replacement[@bib25]PDB: [4F9C](pdb:4F9C){#intref0010}Structure of a pCDK2/CyclinA transition-state mimic[@bib2]PDB: [3QHW](pdb:3QHW){#intref0015}CDC7-DBF4 heterodimer in complex with XL413This workPDB: [6YA6](pdb:6YA6){#intref0020}CDC7-DBF4 bound to ADP-BeF~3~^-^This workPDB: [6YA7](pdb:6YA7){#intref0025}CDC7-DBF4 bound to bisubstrate peptideThis workPDB: [6YA8](pdb:6YA8){#intref0030}**Oligonucleotides**Forward primer λPPase\
5′-TGCGCTATTACGAAAAAATTGATGGSigma-AldrichN/AReverse primer λPPase\
5′-GCGCGTCGACTGCGCCTTCTC\
CCTGTACCSigma-AldrichN/AForward primer HRV14 3C\
5′-GGACGAATTCGGACCAAACACAGA\
ATTTGCACSigma-AldrichN/AReverse primer HRV14 3C\
5′-GGAGCCTCGAGTTATTGTTTCTCTAC\
AAAATATTGSigma-AldrichN/A**Recombinant DNA**pET-λPPase-His6This workN/ApETSUMO-3CThis workN/ApRSFDuet1NovagenCat\# 71341pCDFDuet1NovagenCat\# 71340pRSFDuet-CDC7 (WT and mutants)This work and [@bib25]\<N/A**Software and Algorithms**XDS[@bib33]<http://xds.mpimf-heidelberg.mpg.de/>SCALA[@bib18]<http://www.ccp4.ac.uk/html/scala.html>Xia2[@bib83]<https://xia2.github.io/>Phaser[@bib48]<http://www.ccp4.ac.uk/html/phaser.html>Phenix Autobuild[@bib76]<https://www.phenix-online.org/>phenix.refine[@bib1]<https://www.phenix-online.org/>Refmac[@bib55]<http://www.ccp4.ac.uk/html/refmac5.html>Coot[@bib17]<https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/>MolProbity[@bib82]<http://molprobity.biochem.duke.edu/>PyMOLWarren L. DeLano and Schrödinger LLC<https://pymol.org>

Resource Availability {#sec4.2}
---------------------

### Lead Contact {#sec4.2.1}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Peter Cherepanov (<peter.cherepanov@crick.ac.uk>).

### Materials Availability {#sec4.2.2}

Plasmids generated in this study are available upon request.

### Data and Code Availability {#sec4.2.3}

The coordinates and structure factors were deposited in the Protein Data Bank (PDB) under accession codes [6YA6](pdb:6YA6){#intref0090} (with XL413), [6YA8](pdb:6YA8){#intref0095} (with ADP-BeF~3~^-^), and [6YA7](pdb:6YA7){#intref0100} (with bisubstrate).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

Recombinant proteins were produced in *E*. *coli* cells as outlined in [Method Details](#sec4.4){ref-type="sec"}.

Method Details {#sec4.4}
--------------

### DNA Constructs {#sec4.4.1}

For expression in bacteria, DNA fragments encoding deletion mutants of CDC7 were cloned between *Nco*I and *Xho*I sites of pRSFDuet1 (Novagen) for tag-less expression. A DNA fragment encoding residues 210--350 of human DBF4, extended to include a rhinovirus 3C protease cleavage site (LEVLFQGP), was inserted between the *Eco*RI and *Xho*I sites of pCDFDuet1(Novagen) in frame with the vector sequence encoding a hexahistidine (His~6~) tag. DNA fragment encoding λ phage protein phosphatase ([@bib87]) was PCR-amplified using primers 5′-TGCGCTATTACGAAAAA ATTGATGG and 5′-GCGCGTCGACTGCGCCTTCTCCCTGTACC and λ phage *Hin*dIII digest DNA ladder (New England Biolabs) as template and cloned between *Nde*I and *Sal*I sites of pET20b(+) vector (Novagen), resulting in pET-λPPase-His6. A DNA fragment encoding human rhinovirus 14 (HRV14) 3C protease ([@bib13], [@bib78]) amplified using primers 5′-GGACGAATTCGGA CCAAACACAGAATTTGCAC and 5′-GGAGCCTCGAGTTATTGTTTCTCTACAAAATATTG was digested with *Eco*RI and *Xho*I for ligation into pET28-SUMO (gift from A.L.B. Ambrosio, University of Sao Paulo, Brazil) to obtain pETSUMO-3C.

### Recombinant Proteins {#sec4.4.2}

His~6~-tagged λ phage phosphatase and His~6~-SUMO-tagged HRV14 3C protease were produced in BL21(DE3) cells transformed with pET-λPPase-His~6~ or pETSUMO-3C, respectively, by induction with 300 μM isopropyl-β-D-thiogalactoside (IPTG) in Luria broth (LB) at 25°C. Cells were disrupted by sonication in core buffer (500 mM NaCl, 50 mM Tris-HCl, pH 7.5), and the extracts were clarified by centrifugation. His~6~-tagged proteins were captured by incubation with NiNTA slurry (Qiagen) in the presence of 20 mM imidazole, and the resin was extensively washed with core buffer supplemented with 20 mM imidazole. The proteins, eluted with 200 mM imidazole in core buffer, were supplemented with 10 mM dithiothreitol (DTT). Phosphatase was dialyzed against cold 50 mM NaCl, 2 mM ethylenediaminetetraacetic acid (EDTA), 0.5 mM DTT, 25 mM Tris-HCl, pH 7.5. After 4 h, buffer was exchanged to 50 mM NaCl, 0.1 mM MnCl~2~, 25 mM Tris-HCl pH 7.5, and the dialysis continued for additional 4-6 h, at 4°C. His~6~-SUMO-tagged HRV14 3C protease was purified by size exclusion chromatography through a Superdex 200 16/600 column (GE Healthcare) in 200 mM NaCl, 50 mM Tris-HCl, pH 7.5, supplemented with 10 mM DTT and concentrated using a 10-kDa cutoff VivaSpin-20 device. The proteins (10-20 mg/ml) were supplemented with 10% glycerol, snap-frozen in liquid nitrogen and stored at -80°C in small aliquots.

Production and purification of CDC7-DBF4 complexes was carried out as described previously ([@bib25]), with addition of the dephosphorylation step downstream of His~6~ tag affinity chromatography. Rosetta 2 (DE3) cells co-transformed with compatible CDC7 and DBF4 expression constructs were grown in LB containing 50 μg/ml kanamycin and 100 μg/ml spectinomycin at 30°C. At an A~600~ of 0.9--1.0, the culture was supplemented with 50 μM ZnCl~2~ and 300 μM IPTG. Following overnight induction at 18°C, cells were harvested by centrifugation and stored at -80°C. Cells, thawed in kinase core buffer (50 mM NaH~2~PO~4~, 300 mM NaCl, 10% glycerol, pH 7.5) supplemented with 0.1 mM PMSF, complete EDTA free protease inhibitor mix, 1 mg/ml lysozyme and 0.5% NP40, were lysed by sonication on ice. The extracts, clarified by centrifugation, were supplemented with 20 mM imidazole and incubated with 3 ml Ni-NTA agarose (Qiagen) for 30 min at 4°C with gentle rocking. The resin was washed with 4 changes of 30 ml kinase core buffer supplemented with 20 mM imidazole. Hexahistidine-tagged CDC7-DBF4 heterodimers were eluted in the presence of 200 mM imidazole; fractions enriched in CDC7-DBF4 heterodimers were pooled, diluted with salt-free buffer to adjust NaCl concentration to 200 mM, supplemented with His~6~-tagged λ phage protein phosphatase (1 mg per 15 mg of protein), His~6~-SUMO-tagged HRV14 3C protease (1 mg per 50 mg of protein), 1 mM MgCl~2~, 2 mM MnCl~2~, and 1 mM DTT and incubated overnight at 4°C. Precipitates were removed by centrifugation, and soluble material was dialysed against a large excess of 50 mM Tris-HCl pH 7.5, 100 mM NaCl, 20 mM imidazole, 2 mM DTT for 2-3 h, at 4°C. Dialysed protein was filtered through a 1-ml HisTrap FF column (GE Healthcare) to remove phosphatase and protease. CDC7-DBF4 heterodimers, collected in the flow through, were diluted 1:5 in salt-free buffer to adjust NaCl concentration to ∼80 mM and passed through a 1-ml HiTrap Q HP column (GE Healthcare). CDC7-DBF4 heterodimers, collected in the flow-through, were supplemented with 2 mM DTT and concentrated to ∼5 ml using a 10-kDa cut-off VivaSpin-20 device (Sartorius). Recombinant proteins were then further purified by size exclusion chromatography through a Superdex 200 16/600 column in 150 mM NaCl, 25 mM Tris-HCl, pH 7.5. Fractions enriched in CDC7-DBF4 heterodimers were pooled and dialyzed against excess 150 mM NaCl, 75 μM ZnCl~2~ 2 mM DTT, 25 mM Tris-HCl pH 7.5 overnight at 4°C. The purified heterodimers were concentrated to ∼10 mg/ml for immediate use in crystallography or supplemented with 10% glycerol and snap-frozen in liquid nitrogen for later use in kinase assays.

### Peptides and Bisubstrates {#sec4.4.3}

Peptides were assembled with C-terminal amides following the standard Fmoc chemistry using a 433A instrument (Applied Biosystems) on Rink Amide resin (Sigma-Aldrich). To allow conjugation to ATPγS, the target Ser residue was replaced with aminoalanine using the derivative N-α-Fmoc-N-β-4-methyltrityl-L-diaminopropionic acid. After chain assembly, the side chain methyltrityl group was selectively removed by treatment with 1% trifluoroacetic acid (TFA), 4% triisopropylsilane in dichloromethane. A bromoacetyl moiety was linked to the aminoalanine by reacting the peptidyl-resin with 8.3 eq of bromoacetic acid, 8.3 eq of diisopropylcarbodiimide in a minimum amount of dimethylformamide under stirring condition for 2 h, at ambient temperature. Peptides, released from the resin by treatment with 95% TFA, 2.5% triisopropylsilane, 2.5% water for 2 h, were precipitated with diethyl ether, re-dissolved in water and lyophilized. Peptides were purified by reverse-phase HPLC using 1% acetonitrile, 0.08% TFA in water (buffer A) and 90% acetonitrile, 0.08% TFA in water (buffer B). The ATPγS-peptide conjugates were obtained through a thioether bond formation by reacting the sulfhydryl group of ATPγS and the bromoacetyl moiety. In reported methods ([@bib62]), the purified bromoacetylated peptide was dissolved in a solution methanol:water (4:1) and treated with ATPγS for 24 h at room temperature. For peptides used in this study, triethylammonium bicarbonate buffer (1 M, pH 8.4-8.6) was used to perform this reaction since the bromoacetylated peptides were not soluble in the methanol:water (4:1) solution. Identities and purities of the final products was verified using in-line liquid chromatography mass spectrometry in negative ion mode. Several ATPγS-peptide conjugates were produced, and crystallisation was successful with ATPγS-S40-MCM2(33-47) bisubstrate, containing modified MCM2(33-47) peptide ^33^RRTDALTZ\[pS\]PGRDLP^47^, where Z and \[pS\] stand for amino alanine and phosphoserine, respectively. The former, replacing natural Ser40 of MCM2, was covalently linked to ATPγS as described above.

### *In Vitro* Kinase Activity Assays {#sec4.4.4}

CDC7 kinase assays were carried out essentially as described ([@bib25]). The substrate peptide spanning residues 35-47 of human MCM2 (^35^TDALTS\[pS\]PGRDLP^47^) was synthetized with a phosphate group attached to Ser41 (\[pS\]) and N-terminally biotinylated. Each 25-μl kinase reaction contained 5 μg biotinylated substrate, 2.8 nM CDC7-DBF4 heterodimer and 3 μCi of \[γ-^32^P\]ATP (3,000 Ci/mmol) in 10 mM MgSO~4~, 2 mM DTT, 1 mM β-glycerophosphate, 1 mM NaF, 80 μg/ml bovine serum albumin (BSA), 0.1% Nonidet P-40, 0.1 mM ATP, and 40 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid-NaOH, pH 7.4. Reactions were allowed to proceed for 30 min at 30°C and were terminated by addition of guanidine hydrochloride to a final concentration of 2.5 M prior to spotting onto SAM2 biotin-capture membranes (Promega). The membranes were washed sequentially with 2 M NaCl (three times), 2 M NaCl in phosphate buffered saline (PBS, four times), distilled water (twice), and 95% ethanol. Air-dried membranes were exposed to a phosphor storage screen, and incorporated ^32^P was quantified using a Storm-860 scanner (GE Healthcare).

### Crystallisation, X-Ray Data Collection and Structure Refinement {#sec4.4.5}

Crystals were grown in hanging drops by mixing 1 μl CDC7(Δ1-36/Δ228-345/Δ467-533)-DBF4^MC^ heterodimer (10 mg/ml, supplemented with ligands as required) with 1 μl reservoir solution and equilibrating against optimized reservoir solution by vapour diffusion at 18°C. To crystallise the complex with XL413, the heterodimer supplemented with 5 mM inhibitor was mixed with and equilibrated against 21% polyethylene glycol (PEG) 1500, 5 mM MgCl~2~, and 0.1 M MIB (sodium malonate/imidazole/boric acid buffer system, Molecular Dimensions), pH 5.5. The crystals were cryoprotected by soaking in 5-μl drops containing 2.5 mM XL413, 100 mM NaCl, 2.5 mM MgCl~2~, 10 mM Tris-HCl and 80 mM MIB, pH 5.5, with stepwise increases in PEG1500 (in 1% steps) and PEG400 (5% steps) to the final concentrations of 24% and 20%, respectively.

Microseeding using crushed crystals of the kinase-XL413 complex was used to nucleate the remaining two crystal forms of the CDC7(Δ1-36/Δ228-345/Δ467-533)-DBF4^MC^ heterodimer described in this work. Crystals of the heterodimer in the presence of 2 mM ADP and 2 mM BeF~3~ were grown using reservoir solution containing 21% PEG1500, 15% v/v acetonitrile, 20 mM MgCl~2~, and 0.1 M MMT (DL-malic acid/2-N-morpholinoethanesulfonic acid/Tris buffer system, Molecular Dimensions), pH 6.57. The crystals were cryoprotected by soaking in 5-μl drops containing 75 mM NaCl, 20 mM MgCl~2~, 1 mM ADP, 5 mM Tris-HCl, 70 mM MMT, pH 6.57, 15% acetonitrile, 1 mM BeF~3~ with stepwise increases in PEG1500 (in 1% steps) and MPD (5% steps); the optimal cryogenic condition was achieved with a combination of 22% PEG1500 and 20% MPD.

Crystals of CDC7(Δ1-36/Δ228-345/Δ467-533)-DBF4^MC^ in complex with ATPγS-S40-MCM2(33-47) bisubstrate were likewise nucleated by streak seeding and grown in 18% PEG1500, 8% MPD in 0.1 M PCTP (sodium propionate/sodium cacodylate trihydrate/Bis-Tris propane buffer system, Molecular Dimensions), pH 6.5. For cryoprotection, crystals were incubated in 5-μl drops containing 1 mM ATPγS-S40-MCM2(33-47), 75 mM NaCl and 80 mM PCTP, pH 6.5 with stepwise increases in PEG1500 (in 1% steps) and MPD (5% steps) to the final concentrations of 19% and 20%, respectively.

Cryoprotected crystals were snap-frozen by plunging in liquid nitrogen. X-ray diffraction data on the crystals of the CDC7(Δ1-36/Δ228-345/Δ467-533)-DBF4^MC^ heterodimer complex in complex with XL413 were collected on beamline BM14 of the European Synchrotron Radiation Facility (ESRF, Grenoble, France). Diffraction of the remaining two crystal forms was measured on beamline I03 of the Diamond Light Source (Oxfordshire, UK). The data were integrated and merged using XDS ([@bib33]) and Scala ([@bib18]) via Xia2 automatic pipeline ([@bib83]). The structures were solved by molecular replacement in Phaser ([@bib48]), using the previously reported structure (PDB: [4F9C](pdb:4F9C){#intref0105}) ([@bib25]) as a search model; the extended KI-2 was built using Phenix Autobuild ([@bib76]). The models were iteratively improved by manual building into *Fo-Fc* difference maps in Coot ([@bib17]) and refinement in Refmac ([@bib55]) and/or Phenix refine ([@bib1]). Quality of the refined models was evaluated using MolProbity ([@bib82]). X-ray data reduction and final model quality statistics are given in [Table 1](#tbl1){ref-type="table"}. Protein structure images were generated using PyMOL software (<https://pymol.org>).

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

Statistics generated from X-ray data processing, model refinement and validation are shown in [Table S1](#mmc1){ref-type="supplementary-material"}. *In vitro* kinase assays were carried out in triplicate, all standard deviations were calculated using n-1 method, as implemented in Excel (Microsoft).
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